{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:42:36Z","timestamp":1759383756397},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Weltweit nimmt die Anzahl myoper Menschen stark zu, und damit wird zuk\u00fcnftig auch die Zahl der Patienten mit Folgeerkrankungen wie myoper Makulopathie und Netzhautabl\u00f6sungen steigen. Daher\n\t\t\t\t\tsind pr\u00e4ventive Ans\u00e4tze in den Fokus ger\u00fcckt, die die Progression der Myopie im Kindes- und Jugendalter reduzieren sollen. Neben der Modifikation von Umweltfaktoren sind pharmakologische und\n\t\t\t\t\toptische Methoden m\u00f6glich.<\/jats:p>","DOI":"10.1055\/a-1967-2585","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:01:08Z","timestamp":1668729668000},"page":"99-111","source":"Crossref","is-referenced-by-count":2,"title":["Myopie(progression) \u2013 welche pr\u00e4ventiven Ans\u00e4tze sind sinnvoll?"],"prefix":"10.1055","volume":"240","author":[{"given":"Bettina","family":"Wabbels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"B A Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"ref2","first-page":"3633","article-title":"Parental myopia, near work, school achievement, and children\u02bcs refractive error","volume":"43","author":"D O Mutti","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref3","first-page":"855","article-title":"Prevalence and time trends in myopia among children and adolescents","volume":"117","author":"A K Schuster","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1167\/iovs.13-12403","article-title":"Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET)","volume":"54","author":"COMET Group","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.62.5.7","article-title":"IMI 2021 Yearly digest","volume":"62","author":"M Jong","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.62.5.1","article-title":"IMI 2021 Reports and digest \u2013 reflections on the implications for clinical practice","volume":"62","author":"J S Wolffsohn","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI Prevention of Myopia and Its Progression","volume":"62","author":"J B Jonas","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"W H Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5\u200a%, 0.1\u200a%, and 0.01\u200a% doses (atropine for the treatment of myopia 2)","volume":"119","author":"A Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (lamp) study: a randomized, double-blinded, placebo-controlled trial of 0.05\u200a%, 0.025\u200a%, and 0.01\u200a% atropine eye drops in myopia\n\t\t\t\t\tcontrol","volume":"126","author":"J C Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05\u200a% compared to 0.01\u200a% for myopia control in German school children: a pilot study","volume":"41","author":"L Joachimsen","year":"2021","journal-title":"Int Ophthalmol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"J R Polling","year":"2016","journal-title":"Eye (Lond)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2020.10834","article-title":"Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: The BLINK randomized clinical trial","volume":"324","author":"J J Walline","year":"2020","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"M106","DOI":"10.1167\/iovs.18-25958","article-title":"IMI \u2013 Interventions Myopia Institute: Interventions for controlling myopia onset and progression report","volume":"60","author":"C F Wildsoet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref15","first-page":"1110","article-title":"Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study","volume":"106","author":"C S Lam","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","article-title":"Spectacle Lenses with aspherical lenslets for myopia control vs. single-vision spectacle lenses: a randomized clinical trial","volume":"140","author":"J Bao","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute","volume":"31","author":"J Nemeth","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaophthalmol.2015.0471","article-title":"Prediction of Juvenile-Onset Myopia","volume":"133","author":"K Zadnik","year":"2015","journal-title":"JAMA Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1967-2585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T09:14:23Z","timestamp":1676020463000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1967-2585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":18,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1967-2585","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}